Cloverleaf Bio is developing engineered transfer RNA therapies that use a modified tRNA payload to inhibit cancer cells' RNA-modifying enzymes. Its lead program targets liver cancer and is advancing toward clinical testing; a second antibody-tRNA program for colorectal cancer remains preclinical.
Draper Associates
Activity from announced rounds
Draper Associates is a global venture firm investing in AI, robotics, blockchain, healthcare, biotechnology, aerospace and other emerging technologies.
Its blockchain thesis includes decentralised finance, tokenised assets and decentralised infrastructure. In healthcare, it focuses on technologies such as AI diagnostics, regenerative medicine and neurotechnology that can improve prevention and healthy lifespan.
The firm also backs automation and human-machine collaboration, alongside space technologies. Founders can submit a pitch directly through its website, which also provides an AI pitch-coaching tool.
Sources
- Rounds participated in
- 4
- Confirmed lead rounds
- 0 2 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $92.4M 3 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionDevelops cell therapies using proprietary Cellgorithm platform for regenerative medicine
Apoha measures molecular behavior for pharmaceutical, food and materials research.
Develops AI-driven drug discovery platform for first- and best-in-class therapeutics